Sugar-Based Excipients Market worth 1,060.6 Million USD by 2021

The sugar excipients market has witnessed healthy growth during the last decade, and is expected to grow at a CAGR of 4.3% between 2016 and 2021 to reach USD 1,060.6 Million by 2021.

Browse 125 market data tables and 34 figures spread through 187 pages and in-depth TOC on “Sugar-Based Excipients Market”
https://www.marketsandmarkets.com/Market-Reports/sugar-based-excipient-market-242342136.html

Growth in this market can be attributed to factors such as increasing use of co-processed excipients, rapid growth in the generics market due to the patent expiration of many blockbuster drugs, and increasing development of orally disintegrating tablets (ODTs).

The global sugar excipients market is segmented based on product, type, functionality, formulation, and region. Based on product, the market is segmented into actual sugars, sugar alcohols, and artificial sweeteners. Based on type, the market is segmented into powders/granules, direct compression sugars, crystals, and syrups. Similarly, on the basis of functionality, the market is segmented into fillers & diluents, flavoring agents, tonicity agents, and other functionalities. Based on formulation, this market is segmented into oral formulations, parenteral formulations, topical formulations, and other formulations. Based on regions, the sugar excipients market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.

In 2015, actual sugar accounted for the largest share of the global sugar excipients market. The sugar alcohols segment is expected to witness the highest growth in the next five years primarily due to the rising use of mannitol in a wide range of dosage forms such as oral and topical, and its high adaptability in emerging formulation technologies, such as orally disintegrating tablets. On the basis of type, powders/granules segment accounted for the large share of the global sugar excipients market. The large share of the powders/granules segment is mainly attributed to its wide use in various types of formulations in the pharmaceutical industry. Based on functionality, fillers & diluents segment accounted for the largest share in this market. The large share of this segment is primarily attributed to huge utilization of fillers and diluents in the development and production of oral dosage forms such as tablets, capsules, and syrups. On the basis of formulation, oral formulations accounted for the largest share in the global sugar excipients market due to it increased use of oral formulations such as tablets, capsules, solutions, and emulsions for various therapeutic areas.

Europe is the largest regional segment for the global sugar excipients market. The large share of this regional segment can be attributed to increasing investments in drug development, increasing production of generic drugs, and favorable government initiatives in the region. The market in the Asia-Pacific region is expected to register the highest CAGR owing to the significant growth in the regional healthcare market as well as the pharmaceutical industry, growing scientific base and capability, and favorable government policies, and low-cost manufacturing advantage in this region.

Roquette Group (France), DFE Pharma (Germany), BASF SE (Germany), and Ashland Inc. (U.S.), held the major share of the sugar excipients market, and are expected to dominate the market during the forecast period. Other major players in this market are Associated British Foods Plc (U.K.), Cargill, Inc. (U.S.), Colorcon, Inc. (U.S.), FMC Corporation (U.S.), MEGGLE AG (Germany), and The Lubrizol Corporation (U.S.).

About MarketsandMarkets™

 

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.